Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Lifted by Braidwell LP

Braidwell LP lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 5.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,707,255 shares of the biopharmaceutical company’s stock after buying an additional 146,682 shares during the quarter. Xenon Pharmaceuticals makes up 3.0% of Braidwell LP’s holdings, making the stock its 7th largest holding. Braidwell LP owned 3.57% of Xenon Pharmaceuticals worth $106,585,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of XENE. Blue Trust Inc. lifted its stake in Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter worth $102,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 487 shares in the last quarter. Quarry LP lifted its stake in Xenon Pharmaceuticals by 207.7% in the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Xenon Pharmaceuticals in the 1st quarter worth about $287,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now directly owns 23,573 shares in the company, valued at $968,378.84. This trade represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $43.15 on Friday. The firm’s 50 day moving average price is $41.42 and its 200-day moving average price is $40.24. Xenon Pharmaceuticals Inc. has a 52-week low of $33.62 and a 52-week high of $50.99. The company has a market cap of $3.29 billion, a PE ratio of -15.30 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the company earned ($0.73) EPS. On average, analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XENE has been the topic of a number of research reports. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $57.45.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.